⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Figure 7 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors

View Full Paper

Ask AI

Bookmark

Share

Abstract

Orthogonal combination experiments of HER3 targeting ADCs and trafficking parameters of AMT-562.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Weng et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875238f8 https://doi.org/10.1158/1535-7163.27036163.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 7 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
2Supplementary Figure 6 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
3Supplementary Figure 6 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
4Supplementary Figure 5 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024
5Supplementary Figure 5 from AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors2024